Glaxo’s nucleoside analog 3TC
Executive Summary
Is in two Phase II/III trials in North America involving a total of 645 AIDS patients. One trial involves a comparison of three treatment groups: low dose 3TC with AZT (Burroughs Wellcome's Retrovir) versus high dose 3TC with AZT versus ddC (Roche's Hivid) with AZT in treating HIV-infected, AZT-experienced ( >/= 24 weeks) patients with CD4 cell counts of 100-300/mm. The other study involves a comparison of four arms: 3TC alone, AZT alone, low dose 3TC with AZT and high dose 3TC with AZT in HIV- infected patients, who are AZT naive ( </= 4 weeks) with CD4 cell counts of 200-500/mm. "The Pink Sheet" (Nov. 8, T&G-5) incorrectly described the total number of patients and design of the protocols.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth